U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Guidance, Compliance, & Regulatory Information
  4. Human Drug Compounding
  5. Inter-governmental Working Meeting on Pharmacy Compounding, September 26-27, 2017
  1. Human Drug Compounding

Inter-governmental Working Meeting on Pharmacy Compounding, September 26-27, 2017

On September 26-27, 2017, the U.S. Food and Drug Administration convened its sixth inter-governmental working meeting of state government officials (including the District of Columbia and Puerto Rico). Attendees included officials from the state Boards of Pharmacy and Health Departments and organizations that represent state officials, including the National Association of Boards of Pharmacy (NABP) and the Federation of State Medical Boards (FSMB), and representatives from the Centers for Disease Control and Prevention (CDC).

The purpose of this meeting was to discuss oversight of compounding, including implementation of the Compounding Quality Act (CQA), which Title I of the Drug Quality and Security Act (DQSA), and to identify opportunities to better protect the public health by strengthening oversight of compounders through improved federal-state collaboration.

FDA previously held inter-governmental working meetings with state officials and their designated representatives in December 2012, and in March 2014, March 2015, November 2015 and November 2016. FDA initiated these meetings after the 2012 fungal meningitis outbreak associated with contaminated compounded drugs, involving illnesses and deaths across many states.

Meeting Presentations

Back to Top